Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) had Normalized Income after Taxes of $-2.06M for the most recently reported fiscal quarter, ending 2025-06-30.
Income Statement Financials | |
-- |
|
$-2.06M |
|
-- |
|
-- |
|
$2.26M |
|
$-2.26M |
|
$0.20M |
|
$-2.06M |
|
$-2.06M |
|
$-2.06M |
|
$-2.06M |
|
$-2.06M |
|
Normalized Income after Taxes |
$-2.06M |
$-2.26M |
|
$-2.26M |
|
23.18M |
|
23.18M |
|
$-0.08 |
|
$-0.08 |
|
Balance Sheet Financials | |
$10.61M |
|
$0.22M |
|
$0.52M |
|
$11.13M |
|
$1.43M |
|
-- |
|
-- |
|
$1.43M |
|
$9.70M |
|
$9.70M |
|
$9.70M |
|
20.69M |
|
Cash Flow Statement Financials | |
$-6.14M |
|
$4.28M |
|
$1.31M |
|
$6.15M |
|
$5.60M |
|
$-0.55M |
|
$0.24M |
|
-- |
|
-- |
|
Fundamental Metrics & Ratios | |
7.42 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-6.14M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-21.21% |
|
-21.21% |
|
-18.48% |
|
-21.21% |
|
$0.47 |
|
$-0.27 |
|
$-0.27 |